

Metabolic liver disease in diabetes - From mechanisms to clinical trials

Stephan Herzig

Non-alcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of the Metabolic Syndrome in obesity. Indeed, progressive NAFLD which can ultimately result in non-alcoholic hepatosteatitis (NASH), liver fibrosis and liver cancer is observed in the majority of patients with obesity and diabetes. As the treatment options for NAFLD are extremely limited to date, NAFLD remains a major unmet clinical challenge for the future.

Here, we will discuss our latest results on the genomic characterization of NAFLD progression and the identification of novel key regulatory hubs in this context. Furthermore, specific nutritional intervention strategies are discussed aiming at providing unprecedented approaches to overcome hepatic metabolic dysfunction during obesity and diabetes.